Lumexa Imaging (LMRI)
Outpatient imaging network with radiologist interpretation and health-system partnerships.
Something off on this page? Send us feedback.
Provides outpatient diagnostic imaging and radiologist interpretations through locally branded centers, health-system joint ventures and professional-services relationships. Revenue is earned per scan and read, supported by centralized scheduling and authorization plus the Connexia teleradiology network.
Operates an outpatient diagnostic-imaging network through its Outpatient Imaging Center and Professional Services businesses. The first provides MRI, CT, PET, X-ray, ultrasound and mammography, along with radiologist interpretations, from locally branded freestanding centers; the second reads studies for third parties, primarily hospital imaging departments.
Builds regional networks across multiple U.S. markets through health-system joint ventures, acquired platforms and de novo sites, while centralizing scheduling, authorization, technology, procurement, sales and management support. Connexia routes studies to subspecialized radiologists for remote interpretation, supplementing independent radiology practices.
Payment is generally tied to scans and interpretations at government-set or negotiated insurer rates. Operations depend on provider referrals, radiologist and technologist capacity, payor network status and reimbursement, joint-venture governance, clinical regulation, and third-party systems that handle images, scheduling, billing and AI-supported workflows.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 28, 2026 | Barclays | Reiterate | Rating: —Target: $9 | Target: $13 |
| Aug 13, 2026 | Deutsche Bank | Target | Target: — | Target: $16 |
| May 20, 2026 | Barclays | Target | Target: — | Target: $9 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $69.7M · Total debt $975.4M · Total assets $1.81B · Shareholders' equity $615.1M
- Revenue
- $264.2M
- Operating income
- $4.4M
- Net income
- $2.7M
No dividends on record.
| Institutions | ≈ 32.92% | 31.63M shares | |
|---|---|---|---|
| 104 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Other | ≈ 67.08% | 64.45M shares | |
| remainder | |||
96.07M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Welsh, Carson, Anderson & Stowe XII, L.P.Institution | 73.09% | 70.22M | filed Feb 13, 2026 |
Brown Advisory IncInstitution | 6.01% | 5.78M | as of Jun 30, 2026 |
Massachusetts Financial Services Co /MA/Institution | 3.59% | 3.45M | as of Jun 30, 2026 |
Think Investments LPInstitution | 2.66% | 2.56M | as of Jun 30, 2026 |
Jupiter Topco LLCInstitution | 2.24% | 2.15M | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- RadNet
Largest direct rival in U.S. outpatient diagnostic imaging.
- HCA Healthcare
Large hospital network with diagnostic and freestanding imaging sites.
- Tenet Healthcare
Hospital and ambulatory network with imaging centers and outpatient sites.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Lumexa Imaging | $10.66 | −0.19% | $1.03B | — | 14.0 | 1.0 | — |
| RadNet | $73.47 | +1.11% | $5.71B | — | 129.3 | 2.5 | +25.0% |
| HCA Healthcare | $438.80 | +3.01% | $92.22B | 14.3 | 14.3 | 1.2 | +8.7% |
| Tenet Healthcare | $264.07 | +1.19% | $21.01B | 10.1 | 12.7 | 1.0 | +6.8% |
| Median | 12.2 | 14.3 | 1.2 | +8.7% |